Rethinking Clinical Trials
DECEMBER 20, 2023
Yet enrollment of ethnic minorities in NIH clinical trials and for trials studying approved devices and drugs remains low. Further efforts are urgently needed to increase diversity in the cardiology workforce, which will improve clinical trial diversity and cardiovascular health for all.
Rethinking Clinical Trials
NOVEMBER 9, 2022
Interventional/Structural Fellow, Cleveland Clinic. Clinical Trial, Medical Education. The goal of the CardioNerds Clinical Trials Network is to pair equitable enrollment with trainee development. Among trial sites with affiliated programs, we invited program directors to nominate fellows to participate.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
NOVEMBER 2, 2022
Amit Goyal of the Cleveland Clinic will present “The CardioNerds Clinical Trials Network: Pairing Equitable Enrollment With Trainee Development.” The CardioNerds Clinical Trials Network pairs equitable clinical trial enrollment with the personal and professional development of fellows in training.
XTalks
FEBRUARY 6, 2024
Yet, despite the overwhelming evidence linking CKD with this heightened cardiovascular risk, CKD patients are often underrepresented or outright excluded from cardiovascular clinical trials. Vice President of the Medical Department and Cardiology therapeutic lead, and Heather Lohr, Sr. Director of Clinical Trial Management.
WCG Clinical
MAY 22, 2023
Despite the growing consensus around the need for diversity in clinical trials, the industry still has a long way to go. 4,5 In fact, lack of representation in clinical trials compromises generalizability of research findings. Increasing Diversity in Clinical Trials: Overcoming Critical Barriers.
Pharmaceutical Technology
JUNE 21, 2023
The regulatory approval was based on the findings obtained from a double-blind, multinational, placebo-controlled, randomised clinical trial conducted in 5,522 chronic coronary disease patients. We are dedicated to addressing heart disease, the leading cause of death, by ensuring all patients have access to LODOCO.”
XTalks
NOVEMBER 19, 2021
Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. In CV clinical trials, cardiac biomarkers are most commonly included in efficacy and safety endpoints.
Expert insights. Personalized for you.
182 
Let's personalize your content